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We present a rapid and powerful inference procedure for identifying loci associated with rare hereditary disorders using Bayesian model
comparison. Under a baseline model, disease risk is fixed across all individuals in a study. Under an association model, disease risk de-
pends on a latent bipartition of rare variants into pathogenic and non-pathogenic variants, the number of pathogenic alleles that each
individual carries, and the mode of inheritance. A parameter indicating presence of an association and the parameters representing the
pathogenicity of each variant and the mode of inheritance can be inferred in a Bayesian framework. Variant-specific prior information
derived from allele frequency databases, consequence prediction algorithms, or genomic datasets can be integrated into the inference.
Association models can be fitted to different subsets of variants in a locus and compared using a model selection procedure. This pro-
cedure can improve inference if only a particular class of variants confers disease risk and can suggest particular disease etiologies related
to that class. We show that our method, called BeviMed, is more powerful and informative than existing rare variant association
methods in the context of dominant and recessive disorders. The high computational efficiency of our algorithm makes it feasible to
test for associations in the large non-coding fraction of the genome. We have applied BeviMed to whole-genome sequencing data
from 6,586 individuals with diverse rare diseases. We show that it can identify multiple loci involved in rare diseases, while correctly
inferring the modes of inheritance, the likely pathogenic variants, and the variant classes responsible.Introduction
Hundredsof thousandsof individualswith rare disorders are
undergoing whole-genome sequencing in an effort to iden-
tify novel disease etiologies, increase our understanding of
biological processes, and improve clinical care.1 Thanks to
theaffordabilityofDNAsequencing,populationassociation
study designs for diseases affecting fewer than 1 in 2,000
people are nowpossible. However, the statistical association
methods required to identify relevant loci need to fulfil
several criteria in order to be well-powered, particularly
when the number of cases with a particular disease is small.
First, they need to allow some sharing of information across
variants because rare diseases are often genetically heteroge-
neous. Second, they need to account for the presence of
pathogenic rare variants that actupondisease risk in adomi-
nant or a recessive manner alongside benign rare variants
that do not affect disease risk. Third, they must be capable
of integratingprior information into the inference regarding
the plausibility of a locus being implicated in a disease and
variant-level co-data on pathogenicity. Such co-data can
be derived from population allele frequency databases,
consequence predictions, conservation-based predictions,
or genomic datasets, for example. Lastly, methods need to
have efficient implementations that enable fast application
across a large number of regions in the genome.
Frequentist association tests for rare variants include
the Burden test and the sequence kernel association test
(SKAT).2 The Burden test regresses the phenotype on a
genetic score obtained by summing allele counts across
all rare variants in a locus. The cohort allelic sums test
(CAST)3 uses a genetic score that is equal to 1 if an individ-1Department of Haematology, University of Cambridge, Cambridge Biomedica
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recessive) inheritance model, and 0 otherwise, but is statis-
tically equivalent to the Burden test in other respects. SKAT
specifies a random effect for each variant and performs a
score test under the null hypothesis that the variance of
the random effects is zero. The variance-covariance struc-
ture of the random effects under the alternative hypothesis
is determined by a kernel function, which would typically
be a weighted genetic correlation across the variants in the
locus. SKAT can incorporate nuisance covariates, accounts
for linkage disequilibrium between variants under consid-
eration, and is well-powered for traits whereby many
different variants in a locus with varying effect sizes and
allele frequencies contribute to the phenotype.
For scientific follow-up, it is important to infer which
variants are likely to be pathogenic, conditional on an as-
sociation being present in a given locus. The backward
elimination4 procedure removes individual variants itera-
tively from the predictors as long as this increases a test
statistic of association (either Burden or SKAT). The adap-
tive combination of p values (ADA)5 algorithm ranks var-
iants by p value obtained using Fisher’s exact test and
selects a threshold on p value that maximizes an aggre-
gate test statistic. As these algorithms prune variants in
a stepwise fashion, they do not explore the full space of
possible combinations of pathogenic variants. It is also
important that inference can be performed sufficiently
quickly to enable applications across tens of thousands
of regions, with tens to hundreds of variants in each
one. The methods above, however, rely on permutations
to obtain empirical p values, rendering them computa-
tionally expensive.l Campus, Cambridge CB2 0XY, UK; 2NHS Blood and Transplant, Cambridge
statistics Unit, Cambridge Biomedical Campus, Cambridge CB2 0SR, UK
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In principle, Bayesian inference lends itself well to rare
variant association analysis because it provides a coherent
framework for sharing information across variants and
provides a natural way of incorporating prior information
on variant pathogenicity. The variational Bayes discrete
mixture method (vbdm),6 the Bayesian risk index,7 and
the Bayesian rare variant detector (BRVD)8 all model a
mixture of pathogenic and non-pathogenic variants in a
locus, but they employ additive models of disease risk or
severity more suited to complex rather than rare diseases
caused by dominant or recessive inheritance of one or
two pathogenic alleles.
Here we present a Bayesian model in which disease
risk depends on the genotypes at rare variants in a locus,
a latent mode of inheritance, and a latent partition of
variants into pathogenic and non-pathogenic subsets.
Different modes of inheritance are modeled by condition-
ing the probability of case status on the number of patho-
genic alleles and the ploidy for each individual at the
variants. Thus, disease risk due to compound heterozygos-
ity or X-linked inheritance is explicitly accommodated.
Prior knowledge concerning variant pathogenicity can be
incorporated in the form of shifts in the log odds of path-
ogenicity relative to a global mean. By placing a vague
prior distribution on the scale of these shifts, the useful-
ness or otherwise of these co-data are accounted for flex-
ibly to maximize power.
For a given set of variants, inference is performed by
comparing the model described above with a baseline
model in which disease risk is independent of the geno-
types. The mode of inheritance and the pathogenicity of
each variant, conditional on an association, can be in-
ferred through the posterior distributions of parameters
in the model. Particular classes of variants in a locus may
be the only ones that confer disease risk. For example,
only variants in the 50 UTR region or only high-impact cod-
ing variants may be involved. Our method can compare
models fitted to different classes of variants in order to
infer which ones are responsible for disease. Typically the
inference process would be repeated over many sets of var-
iants selected from different loci throughout the genome.
The procedures are implemented in an efficient R package
called BeviMed, which stands for Bayesian evaluation of
variant involvement in Mendelian disease.Material and Methods
Model Specification
Let y be a binary vector of lengthN indicating whether individual i
is a case (yi ¼ 1) or a control (yi ¼ 0) subject with respect to a
particular disease. Suppose k rare variants are under consideration
(typically in a particular genomic region) and the genotype for in-
dividual i at variant j is coded in the ith row and jth column of
the genotypematrixG. A genotype of 0 or 2 denotes homozygosity
for the common or minor allele, respectively, and a genotype of 1
denotes heterozygosity. Under a baseline model, labeled g ¼ 0, y
is independent of G and all individuals have a probability of beingThe Ama case t0. Under the association model, labeled g ¼ 1, individuals
either have or do not have a pathogenic configuration of alleles
and have probabilities of being a case subject p and t, respectively.
Whether or not an individual has a pathogenic configuration of al-
leles depends on a function f of the genotypesGi of that individual,
a latent binary vector z indicating which of the k variants are path-
ogenic, a value si equal to the ploidy of the individual at the variant
sites, andavariablem representing themodeof inheritance govern-
ing the disease etiology though the k variants:
g ¼ 0 : Pyi ¼ 1 ¼ t0;
g ¼ 1 : Pyi ¼ 1 ¼

t if f ðGi,; z; si;mÞ ¼ 0;
p if f ðGi,; z; si;mÞ ¼ 1: (Equation 1)
The function f can represent a dominant inheritance model or a
recessive inheritance model that accounts for sex-dependent dif-
ferences in ploidy on the X chromosome (i.e., X-linked recessive
inheritance), depending on variable m˛fmdom;mrecg:
f ðGi,; z; si;mdomÞ ¼ 1P
j
GijzjR1
;
f ðGi,; z; si;mrecÞ ¼ 1P
j
GijzjRsi
:
Thus, the interpretation of z depends on the mode of inheri-
tance. In order to have a pathogenic allele configuration, individ-
ual i requires at least one allele at a variant for which zj¼ 1 under a
dominant model, but si alleles under a recessive model. If geno-
types are phased, then a requirement that the si pathogenic alleles
are on different haplotypes can be imposed. Recent relatedness is a
potential confounder because it is correlated with both case/con-
trol status and genotype and, therefore, only unrelated individuals
should be included in the model.
We place beta priors on all three parameters representing risk of
disease:
t0  Betaða0;b0Þ;
t  Betaðat; btÞ;
p  Betaðap;bpÞ:
The mean risk of disease for individuals without a pathogenic
combination of alleles in the variants under consideration is un-
certain under both models, and thus we place uniform priors on
t0 and t by default. However, as pathogenic combinations of al-
leles typically confer a high disease risk, we suggest setting the hy-
perparameters for p to ap ¼ 6 and bp ¼ 1 (i.e., with a mean of 6/7).
However, the prior mean could be adapted, for example, to reflect
the consistency with which the disease manifests within families.
We adopt a logistic regression framework for the prior probabil-
ity that the variants are pathogenic. The logit of the prior probabil-
ities are shrunk toward a common mean, u. If prior information
that discriminates between the likely pathogenicity of variants is
available, it can be incorporated in the form of a covariate c with
regression coefficient f in the regression equation:
zj  Bernoulli

pj

;
logit pj ¼ uþ fcj:erican Journal of Human Genetics 101, 104–114, July 6, 2017 105
One would typically place a Gaussian prior on the intercept u
but, for computational purposes, we prefer to use a logit-beta prior
with hyperparameters au and bu (see Appendix A). The prior mean
of u should reflect the expected proportion of variants that are
pathogenic, conditional on an association, and may depend on
the filtering procedures used to select the variants to include in
the model. By default, pðuÞ reflects a prior expectation that 20%
of variants are pathogenic and a prior probability of only 0.01
that the proportion of pathogenic variants exceeds 0.54. This prior
is well suited to missense variants but a distribution with a higher
mean should be specified if most variants are expected to be path-
ogenic. This would be the case if the variants under consideration
are all protein truncating and thought to be functionally equiva-
lent to each other. To ensure that u can be interpreted as the global
mean log odds of pathogenicity, the c are required to sum to zero.
Thus, any user-supplied weights, ~cj, are centered such that
cj ¼ ~cj  ð1=kÞ
P
l
~cl. We place a log-normal prior on the regression
coefficient f to force the effects of the cj to be the same as their
signs. The prior mean of f is set to 1 so that the cj are interpretable
as prior shifts in the log odds of pathogenicity relative to the
mean. A prior variance on f of 0.35 ensures that the effect of
the co-data can be diminished if the co-data are not informative
and increased if they improve the model fit.
Finally, the prior probability on the mode of inheritance param-
eter m and the model indicator parameter g need to be specified.
By default, we set the prior probabilities for each mode of in-
heritance given an association to be the same, i.e., Pðm ¼
mdom jg ¼ 1Þ ¼ 0:5, and we assume that there is only a 1% chance
a priori of an association, i.e., Pðg ¼ 1Þ ¼ 0:01. However, for a
particular set of variants, the choice of values for these parameters
could be based on the scientific literature or reference variant da-
tabases, for example.Inference
The principal quantity of interest is the posterior probability of the
model indicator g, which can be derived from a Bayes factor
comparing the two models and PðgÞ. The Bayes factor has two
components, the evidence under g ¼ 0 and the evidence under
g ¼ 1. A closed-form expression exists for the evidence under
either model and it can be computed rapidly under g¼ 0, irrespec-
tive of y. However, the expression for the evidence under g ¼ 1
contains a sum over every possible value of z, of which there are
2k, and k is usually large enough to render this sum computation-
ally intractable.
To tackle this problem, we reviewed various methods for esti-
mating the evidence of a model9 and chose the method of power
posteriors,10 which enables the evidence to be estimated by Mar-
kov chain Monte Carlo (MCMC) sampling. In this method, the
MCMC is tempered, which is helpful in a variable selection setting
such as ours because it makes exploration of the space of sets of
pathogenic variants more efficient. Samples are drawn from a se-
ries of related distributions called power posteriors. Each power
posterior has a temperature t between 0 and 1 and is proportional
to the likelihood of the parameters to the power of t times the
prior. These samples can be combined to obtain an estimate of
the integrated likelihood (see Appendix A).
Sampling for our model can be done very efficiently because
an MCMC update to zj entails changes only in f ðGi,; z; si;mÞ for
individuals for whomGij> 0. For convenience, we estimate the ev-
idence conditional onm but we can integrate over it through sim-
ple summation. Once theMCMC samples have been collected, the106 The American Journal of Human Genetics 101, 104–114, July 6, 2marginal posterior probability of z given g and m can be obtained
directly and used for ranking variants by their likely pathogenicity.
The estimated number of pathogenic variants and the expected
posterior number of case subjects explained by the pathogenic var-
iants, given g ¼ 1, can also be computed (see Appendix A). The
posterior probability of g provides a natural means of ranking
sets of variants from different loci across the genome.
The model above assumes that the prior probabilities of variant
pathogenicity are conditionally independent. However, particular
classes of variants in a locus may confer disease risk, while others
may be benign. We can impose a prior correlation structure on
the z reflecting these competing hypotheses by fitting a different
association model for each class of variant. If one of the hypoth-
eses matches the true etiology of disease, then this modeling
approach can improve model fit and thus increase power. Let
g˛f1;2;.; gg index the association models and let Iuv indicate
whether variant v is included in association model u. Then, we
can compute the probability of association across the competing
models as:
Pðg > 0 j y;G; c; IÞ ¼
Pg
u¼1P

y j g ¼ u;GðuÞ; cðuÞPðg ¼ uÞPg
u¼0Pðy j g ¼ u;GðuÞ; cðuÞÞPðg ¼ uÞ
;
where GðuÞ ¼ G,fv:Iuv¼1g and cðuÞ ¼ cfv:Iuv¼1g. The prior on the model
indicator, PðgÞ, can be informed by external data. For example, if a
gene has a high probability of loss-of-function intolerance,11 then
the prior corresponding to a model of high-impact variants in
that gene could be up-weighted relative to competing models.
We can also compute the posterior probability of variant pathoge-
nicity averaged over all association models using the following
expression:
Pðz j g > 0; y;G; c; IÞ
¼
Pg
u¼1P

z j g ¼ u; y;GðuÞ; cðuÞ Pg ¼ u j y;GðuÞ; cðuÞPg
u¼1Pðg ¼ u j y;GðuÞ; cðuÞÞ
:
Other quantities of interest, such as the expected posterior num-
ber of cases explained by pathogenic variants, can be averaged
over models in the same way.Simulation Set-Up
We conducted a simulation study under different scenarios and us-
ing different methods in order to evaluate power to detect associ-
ations, to assess accuracy in variant pathogenicity classification,
and to investigate the effect of integration of variant-level co-
data on inference. We generated random allele count matrices
for 1,000 individuals at k rare variant sites with allele frequencies
of 0.0017 and 0.03 for the dominant and recessive modes of
inheritance, respectively. We used k ¼ 25 for the main simulation
study.We labeled the first five variants pathogenic and the remain-
ing variants non-pathogenic. The case/control labels were simu-
lated using the expression in Equation 1, assuming si ¼ 2 (i.e.,
diploidy), a particular mode of inheritance (either dominant or
recessive), and a particular combination of values for t and
p˛f0; ð1=10Þ; ð2=10Þ;.;1g such that p > t. Our selection of t
and p is comprehensive but for rare diseases we would expect
t < 0.5 and p[ 0.5. For each combination of mode of inheri-
tance, value of t, and value of p, 5,000 allele count matrices
were generated and 5,000 corresponding case/control vectors
were generated. The 5,000 datasets were copied and the case/con-
trol labels corresponding to the copied set were permuted to break
the association between the genotypes and the phenotype. Thus,017
under each scenario, we had a pool of 10,000 datasets, of which
half were generated under a model of association and half were
generated under a model of no association.
In order to assess the performance of different methods in a
realistic setting, we evaluated their ability to rank non-permuted
datasets among a large set of permuted datasets. Under each simu-
lation scenario, we generated mixtures of 10 non-permuted and
990 permuted datasets selected at random from the corresponding
pool. We then applied each method and computed the mean pos-
itive predictive value (PPV), over 10,000 repetitions, at 80% power.
The PPV, which is equal to one minus the false discovery rate
(FDR), is inversely related to power. Thus, a higher PPV for a given
power implies greater power for a given FDR. We preferred to eval-
uate PPV for a given power rather than power for a given FDR
because empirical power changes monotonically as the rank
threshold for declaring a positive result is lowered, while the
empirical FDR does not.
We selected the methods ADA, CAST, and SKAT for comparison
as they represent diverse approaches: ADA enables individual
variant-level inference, CAST is based on the popular Burden test
but can account for either dominant or recessive inheritance
modes, and SKAT is a popular and flexible method designed for
rare variants affecting complex traits. The default linear kernel
function for SKAT is used here. The other methods mentioned
above were either inapplicable (e.g., vbdm requires a continuous
response), unavailable (BRVD), or shown to be inferior to ADA
in a previous publication.12 Note that ADA p values were
computed using 10,000 permutations instead of the default
1,000 in order to reduce the number of ties (parts of the ADA
code were re-implemented in Cþþ in order to complete our simu-
lation study in a reasonable amount of time; modified code avail-
able on request).
The results were ranked based on the posterior probability that
g ¼ 1 for BeviMed and the negative log p value of association for
the other methods. Variants were ranked according to BeviMed’s
marginal posterior probability for the components of z and ac-
cording to inclusion in ADA’s variant selection. The othermethods
do not provide variant-level inference. Although the backward
elimination procedure is implemented for SKAT, it is so slow as
to make its use impractical in even a moderately sized study
such as this.
To demonstrate the effect of including prior information
regarding variant pathogenicity on BeviMed’s inference, we con-
ducted a further study whereby we simulated datasets with m ¼
mdom, t ¼ 0.2, and p ¼ 0.85 and modified the values of the
variant-specific co-data ~cj as follows. The values of ~cj for all vari-
ants was set to either 1 or 0. The number of truly pathogenic var-
iants that were assigned the value 1 was set to 0, 1, 2, 3, 4, or 5,
and the number of truly non-pathogenic variants that were as-
signed the value 1 was set to 0, 4, 8, 12, 16, or 20. Thus, the pro-
portions of correctly and incorrectly up-weighted variants were
varied between 0 and 1 in increments of 0.2. In the extreme,
the co-data could support the true classification exactly or sup-
port the inverted classification exactly. As SKAT can incorporate
variant-specific relative weights, we applied it to the same simu-
lated data, setting SKAT’s weights for up-weighted variants to
twice that of the others. This choice of up-weighting factor
was as low as possible while ensuring that, when the weights
were perfectly concordant with the true pathogenicity of the var-
iants, the PPV was approximately the same for SKAT as for
BeviMed. Expected PPV at 80% power was estimated as described
above, based on 5,000 truly associated and 5,000 permuted data-The Amsets, for BeviMed and SKAT under each combination of pro-
portions of correctly up-weighted and incorrectly up-weighted
variants.Application to Real Data
The NIHR BioResource–Rare Diseases has generated whole-
genome sequencing data for 6,586 unrelated individuals with
diverse rare diseases in an effort to identify novel genetic etiol-
ogies. We applied BeviMed to the data, setting the case/control
status based on two dichotomous phenotypes represented in
the study: pathologically low numbers of platelets in the blood
stream (thrombocytopenia) with absence of syndromic features
ðPiyi ¼ 184Þ and Roifman syndrome ðPiyi ¼ 3Þ.
Hereditary thrombocytopenia can be caused by variants in a
large number of genes with diverse functions, including genes en-
coding transcription factors, cytoskeletal proteins, and membrane
proteins.13 Severe thrombocytopenia is typically monogenic and
non-syndromic forms are usually dominant. Roifman syndrome
(MIM: 616651) is a rare autosomal-recessive disease with symp-
toms including growth retardation, spondyloepiphyseal dysplasia,
and cognitive delay, initially described by Roifman et al.14 Last
year, variants in the non-coding gene RNU4ATAC (MIM: 601428)
were identified as the cause of this disease on the basis of pedigree
studies involving six case subjects.15 Within the bleeding and
platelet disorders branch of the NIHR BioResource dataset, three
unrelated case subjects with Roifman were enrolled because they
presented with immune thrombocytopenia.
For each gene, we considered single-nucleotide variants (SNVs)
and short insertions/deletions (indels) with an allele frequency
in ExAC11 and the whole-genome sequencing component of
UK10K16 less than 1/1,000 and large deletions overlapping exons
with an internal frequency less than 1/1,000. SNVs and indels had
to have a HIGH or MODERATE Variant Effect Predictor (VEP)17
impact or they had to have a VEP Sequence Ontology-coded
consequence that included non_coding_transcript_exon_variant,
5_prime_UTR_variant, or 3_prime_UTR_variant. If a variant had
consequences in relation to multiple transcripts of the same
gene, only the highest-impact consequence was retained. In total,
we considered 1,338,830 variants in 35,205 gene loci, each con-
taining between 1 and 2,615 variants.
We setPðm ¼ mdom jg ¼ 1Þ to 0.8 for thrombocytopenia and 0.1
for Roifman syndrome, to reflect the belief that these diseases tend
to be dominantly and recessively inherited, respectively. For each
locus, we considered four association models corresponding to
four classes of variants:
d High: large deletions and variants with a HIGH impact
annotation
d Moderate: variants with a MODERATE or HIGH impact
annotation or a consequence including non_coding_
transcript_exon_variant but none of the UTR-related
consequences
d 50UTR:variantswithout aMODERATEorHIGH impact anno-
tation and a consequence including 5_prime_UTR_variant
d 30 UTR: variants without a MODERATE or HIGH impact
annotation and a consequence including 3_prime_UTR_
variant
The hyperparameters were assigned default values except for au
and bu, which we set to (2,1) instead of (2,8) under the ‘‘high’’
model. This reflects a belief that a greater proportion of variantserican Journal of Human Genetics 101, 104–114, July 6, 2017 107
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Figure 1. Simulation Study
(A and B) Results of the simulation study. Mean PPV at power of 80% over repeat simulation of the BeviMed, SKAT, ADA, and CAST rare
variant association tests for data simulated using the expression in Equation 1 for various combinations of values of t and p.
(C) Receiver operating characteristic (ROC) curves for the classification of variants as pathogenic by BeviMed for different values of p.
(D) Left: mean PPV at power of 80% for BeviMed and SKATat t¼ 0.2 and p ¼ 0.85, for varying proportions of pathogenic and non-path-
ogenic variants being up-weighted in the co-data variables. Right: posterior mean of f corresponding to the applications of BeviMed on
the left-hand grid.
(E) Mean PPV at power of 80% over repeat simulation of the BeviMed and SKAT association tests for different values of k.are likely to be pathogenic under the high model than under the
other three models. When we fitted the ‘‘moderate’’ model, we
up-weighted the variants that were also included in the high class
relative to the others by setting their uncentered weights ~cj to 1
rather than 0. For coding loci, we assigned prior probabilities of
0.004, 0.003, 0.002, and 0.001 to the four models above, respec-
tively, in order to reflect the relative biological plausibility of the
different classes of variants being involved in disease. For non-cod-
ing genes, we assigned a prior probability of the moderate model
equal to 0.01. Thus, Pðg > 0Þ ¼ 0:01 for all genes. For complete-
ness, we also applied SKAT to the four classes of variants described
above separately, using default settings, and retained the result
with the lowest p value for each locus.108 The American Journal of Human Genetics 101, 104–114, July 6, 2Results
Simulation Study
Under a dominant model, BeviMed had a slightly higher
PPV than the other methods while, under a recessive
model, it greatly outperformed competing methods:
when p ¼ 0.8 and t ¼ 0.2, BeviMed had a PPV of 100%,
while SKAT, CAST, and ADA had a PPV of 42%, 8%, and
2%, respectively (Figures 1A and 1B). This favorable perfor-
mance was achieved despite using the same priors for
model parameters t and p, irrespective of the values of t
and p used to simulate the data. We note that BeviMed’s017
Table 1. Performance Comparison
Method N ¼ 1,000, k ¼ 25 N ¼ 1,000, k ¼ 100 N ¼ 5,000, k ¼ 25 N ¼ 5,000, k ¼ 100 N ¼ 100,000, k ¼ 1,000
Association Tests with Variant Identification
BeviMed 0.03 0.09 0.07 0.23 38.90
ADA 3.69 11.30 18.76 59.23 –
BE-SKAT 53.46 175.18 137.39 799.80 –
Association Tests without Variant Identification
CAST 0.01 0.01 0.02 0.05 1.77
SKAT 0.02 0.05 0.09 0.30 140.82
SKAT (IBS) 3.73 4.38 548.47 675.62 –
SKAT (quadratic) 4.08 4.12 571.69 598.96 –
SKAT (2wayIX) 4.09 4.37 580.90 575.67 –
Execution times in seconds of different association tests for datasets with different N and k. BE-SKAT refers to SKAT with backward elimination of variants. SKAT
(IBS), SKAT (quadratic), and SKAT (2wayIX) refer to application of SKAT using the weighted identity by state, quadratic, and two-way interactions kernel functions,
respectively. The p values for ADA and BE-SKAT were computed using their default number of permutations, respectively 1,000 and 300. Dashes indicate that the
method took longer than 1 hr to run.performance for t ¼ 0.2 was approximately the same for
the following three pairs of values for the hyperparameters
au and bu: (2,8), which is the default, (1,1), which places a
uniform prior on expitðuÞ, and (2,1), which places higher
prior weight on values of expitðuÞ near 1.
For t ¼ 0.2 and high p, BeviMed was able to provide ac-
curate rankings of variants by estimated pathogenicity,
particularly under a dominant mode of inheritance (area
under the curve ¼ 0.97 at p ¼ 0.9, Figure 1C). ADA’s
average classification of variant pathogenicity at p ¼ 0.9
gave a true positive rate of 0.78 and a false positive rate
of 0.063, while BeviMed’s true positive rate at that same
false positive rate was 0.88.
The results of the simulation study assessing the effect of
incorporating variantweights showthat BeviMed is substan-
tiallymore robust to deleterious weightings (Figure 1D, left).
When the co-data matched the truth perfectly, the power
for BeviMed and SKAT was approximately the same (by
design), but when the co-data was entirely counter-produc-
tive, BeviMed’s PPV was 0.46 and SKAT’s PPV was 0.06.
BeviMed’s advantage was achieved naturally in our Bayesian
setting through modulation of f, which had a posterior
expectation of 1.93 when the co-data was most useful but
only 0.46 when it was least useful (Figure 1D, right).
We evaluated the performance of BeviMed in relation
to the most competitive alternative method, SKAT, using
the same parameters described above, but increasing the
total number variants k to 50, 100, 150, and 200. Power
decreased for bothmethods as the total number of variants
increased, but the discrepancy in power between BeviMed
and SKAT increased (Figure 1E). For example, under the
dominant model, BeviMed’s PPV at k ¼ 200 and p ¼ 1.0
was 83% while SKAT’s PPV was only 34%.
Computational Performance
We compared the execution times of the different associa-
tion tests, including SKAT with backward elimination, onThe Amsimulated datasets generated as described above using
N ˛f1000;5000;100000g, k˛f25;100;1000g, and allele
frequency of 1/1,000. The results, displayed in Table 1,
show that CAST is the fastest method, as it uses a straight-
forward Fisher’s exact test. However, CAST is substantially
less powerful than BeviMed under both dominant and
recessive models (Figure 1). BeviMed has comparable
execution time to SKAT for small datasets and surpasses
it for large datasets, as BeviMed’s complexity scales
with
P
i;jGij > 0, which typically increases only linearly
withN. SKATwas also run using the other kernels available
in the R package: identity by state, quadratic, and two-way
interactions. All three modes were substantially slower
than BeviMed and linear SKAT (Table 1), less powerful
than BeviMed in the simulation study, and less power-
ful than linear SKAT under at least one mode of inheri-
tance. BeviMed has vastly superior performance to the
other methods which can infer the pathogenicity of vari-
ants, while also reporting posterior uncertainty in pathoge-
nicity status. The complete set of applications to the data
from the NIHR BioResource, which comprises 2 pheno-
types, 35,205 loci, 2 modes of inheritance, and 4 variant
classes, took 7 hr to complete using 16 CPU cores.
Identifying Associations with Thrombocytopenia
Themedian value of the posterior probability of association
with thrombocytopenia across all gene lociwas 0.0064. The
independent gene loci for which the posterior probability
of association exceeded 0.9 are shown in Table 2. We
show the posterior probability of association, the posterior
probability of the mode of inheritance parameter, the esti-
matednumber of case subjects explained by the pathogenic
variants, the estimated number of pathogenic variants that
are present in the case subjects, and the total number of
variants considered. These results corroborate established
knowledge of platelet disorders. ACTN1 (MIM: 102575)-
related macrothrombocytopenia is a dominant bleedingerican Journal of Human Genetics 101, 104–114, July 6, 2017 109
Table 2. Independent Loci Having Pðg ¼ 1 j yÞ > 0:9
Locus
Posterior Probability
of Association
Posterior Probability
of Dominance
Modal
Model
Estimated Number of
Explained Case Subjects
Estimated Number of
Explaining Variants
Number of
Variants
ANKRD26 1.000 1.000 50 UTR 10.792 7.792 87
RUNX1 1.000 1.000 moderate 8.153 8.191 214
MYH9 1.000 1.000 moderate 10.964 9.116 141
GP1BB 0.999 1.000 moderate 8.223 7.228 69
ACTN1 0.999 1.000 moderate 9.867 7.867 121
Independent loci with a posterior probability of association with thrombocytopenia greater than 0.9.andplatelet disorder recognized since2013.18GP1BB (MIM:
138720) has traditionally been linked to a recessive
bleeding and platelet disorder called Bernard-Soulier syn-
drome,19 but earlier this year we reported a dominant
mode of inheritance resulting in a milder platelet pheno-
type.20 The posterior on themode of inheritance parameter
strongly favored dominance in this case, which is consis-
tent with an absence of Bernard-Soulier-affected case
subjects in our dataset. RUNX1 (MIM: 151385) encodes a
transcription factor linked with a dominant platelet disor-
der with associated myeloid malignancy. MYH9 (MIM:
160775) harbors variants responsible forMYH9-related dis-
order, which is characterized by macrothrombocytopenia
and occasional Do¨hle-like inclusion bodies in neutrophils
and pathologies of the ear, eye, kidney, or liver. Finally,
variants in the 50 UTR of ANKRD26 (MIM: 610855) were re-
ported to result in non-syndromic macrothrombocytope-
nia in 201121 after an initial erroneous report that variants
in the neighboring gene ACBD5 (MIM: 616618) were
responsible.22 The association we have identified is driven
by variants in the 50 UTR, despite this class of variants being
down-weighted relative to the classes comprising variants
with missense or high-impact predicted consequences on
the translated gene product. The variant level results of
the inference shown in Figure 2 indicate the high posterior
probability of association for the first eight variants in the 50
UTR. It is noteworthy that one of the variants, which
encodes c.113A>C and was reported in a follow-up23 to
the original 2011 paper, does not appear to be pathogenic,
as five out of the six individuals with the variant, including
one homozygous for the alternate allele, do not have a
bleeding or platelet disorder.
Therewere four additional loci havingPðg ¼ 1 j yÞ > 0:9.
They all tagged a true association listed in Table 2 but were
labeledwith the names of neighboring genes andhad lower
posterior probabilities of association. A missense variant
in WAC (MIM: 615049) was in linkage disequilibrium
with one of the 50 UTR variants in ANKRD26, inducing
Pðg ¼ 1 j yÞ ¼ 0:993 for the WAC locus. The other three
results were induced by the presence of deletions in
RUNX1 spanning three neighboring RNA genes or pseu-
dogenes: AF015262.2 (Pðg ¼ 1 j yÞ ¼ 0:978), RPL34P3
(Pðg ¼ 1 j yÞ ¼ 0:976), and EZH2P1 ðPðg ¼ 1 j yÞ ¼ 0:974Þ.
The alternate method that was most powerful based on
the results of the simulation, SKAT, did not rank the loci110 The American Journal of Human Genetics 101, 104–114, July 6, 2listed above as highly, even when only the variant class
with the lowest p value was retained for each gene.
RUNX1, ANKRD26, MYH9, ACTN1, and GP1BB had ranks
of 1, 3, 8, 16, and 74, respectively, with none of the other
loci in the top 20 ranks being known to be implicated in
thrombocytopenia.Identifying Variants Responsible for Roifman Syndrome
The locus with the highest posterior probability of associa-
tion with the Roifman syndrome case label was RNU4ATAC
ðPðg ¼ 1Þ ¼ 1:000Þ, driven by four different single-nucleo-
tide variants in this non-coding gene. Two of the case sub-
jects were compound heterozygous, including for a variant
observed in six control subjects, and one was homozygous.
As all but one of the variants were seen only in heterozygos-
ity, theposterior probability of variant pathogenicity condi-
tional on recessive inheritance was relatively high across
the gene but markedly lower than the causal variants
observed in the case subjects, which had a posterior proba-
bility of pathogenicity very close to 1 (Figure 3). All other
genes had a posterior probability of association less than
0.9 and the expected number of case subjects explained
by the variants in other loci was less than 2. SKAT assigned
RNU4ATAC a p value of 0, but this was also the case for 34
other genes, which were tied in the top rank.Discussion
We have presented a Bayesian genetic association method
for rare diseases that is more powerful than existing
methods, particularly for the recessive mode of inheri-
tance, and provides summary statistics on variant-level
pathogenicity and mode of inheritance very efficiently. It
enables mode of inheritance to be integrated out or in-
ferred from the data. Indeed, we were able to determine a
dominant mode of inheritance for variants in a gene,
GP1BB, that has been associated only with a recessive dis-
order for more than 30 years. Given an association under a
particular mode of inheritance, our method also estimates
the number of case subjects explained by pathogenic vari-
ants and the number of variants that are pathogenic.
Prior information specific to a particular set of variants
under consideration can modulate the evidence of associa-
tion,which canbe criticalwhen thenumberof case subjects017
Figure 2. Posterior Probability of Pathogenicity for Rare Variants in ANKRD26
Results obtained by applying our inference procedure to rare allele counts in ANKRD26 against the thrombocytopenia case/control label.
Exons are represented by gray blocks starting from the 50 UTR on the left and ending with the 30 UTR on the right. The classes that each
variant belongs to are indicated by crosses. The bar chart in the top right shows the posterior probability of each associationmodel under
each mode of inheritance conditional on an association being present at the locus. The gray bars above show the marginal posterior
probabilities of pathogenicity for individual rare variants conditional on an association being present at the locus. The inference algo-
rithmwas runwith 100,000 iterations instead of the usual 1,000 in order to reduce jitter due toMonte Carlo sampling error. The bar chart
beneath shows the breakdown of heterozygous and homozygous carriers of the variants between case and control subjects.with a shared genetic etiology is small. For example, the
prior on the model indicator g can be adjusted to reflect lo-
cus-specific genomic andepigenomic knowledge inorder to
encourage regions with higher prior plausibility of involve-
ment in the disease phenotype to rank more highly than if
the same prior had been used across all regions. The prior
probability of pathogenicity for a particular variant, given
the association model, can be modulated by knowledge
about the variant, such as predicted consequence, allele fre-
quency, or conservation. These variant weights are inter-
pretable as prior shifts in the log odds of pathogenicity,
which provides an intuitive basis for assigning particular
values to them. In sharp contrast to frequentist approaches,
we use a flexible prior on the effect sizes of the weightings
that reflects the uncertainty in their utility.
The results of inference on different subsets of rare vari-
ants in a locus (selected, for example, on the basis of their
predicted consequences) can be interpreted and combined
easily in a Bayesian framework using a model selection pro-
cedure. The posterior probability of variant pathogenicity
andotherquantitiesof interest canbeaveragedovermodels.
In addition to increasing statistical power if particular classes
of variants in a locus are the only ones that confer disease
risk, this feature also allows inference of the kind of variants
responsible fordisease,whichmay suggestparticular genetic
etiologies. In our applications, we were able to identify a set
of variants in the 50 UTR of a gene that causes a platelet dis-
order. Thehighposterior probabilityof pathogenicityof var-
iants in the 50 UTR to the exclusion of coding variants, even
those observed only in case subjects, was made possible by
our model selection procedure.
Variants highlighted by a method such as ours would
usually undergo assessment by a multidisciplinary diag-
nostic team and it would resolve increasing numbers ofThe Amcase subjects over time. In our application to real data,
we have kept the case/control labels the same for each
application. However, in the context of genetically hetero-
geneous diseases, we would recommend relabelling any
case subject whose phenotype has been fully accounted
for by pathogenic or likely pathogenic variants in a
different locus as a control. This boosts specificity as it
makes it less likely for a non-pathogenic rare variant car-
ried by a case to induce a high probability of association.
Themodel assumes that relatedness between individuals
is sufficiently low as not to be associated with either case/
control status or the genotypes. In practice, we recom-
mend removal of any first, second, or third degree relatives.
Ourmethod is designed to be applied to up to thousands of
rare variants at a time and efforts should be made to ensure
all potentially implicated variants in a locus are included in
the model, or the set of models, under comparison. Rare
variants would typically be unlinked within a locus but
may occasionally be linked across loci. For example, large
deletions may span multiple genes and certain pairs of
rare variants could be in linkage disequilibrium. In these
situations, a non-pathogenic rare variant in one locus
linked to a pathogenic variant in another locus could
induce a non-causal association. Such associations can
either be filtered post hoc through comparison of inference
results in nearby loci or avoided altogether by joint
modeling of variants across multiple nearby loci.
Although Bayesian inference is typically thought of as
slow, our implementation can handle data from more
than a million variants spread across tens of thousands
of regions called in thousands of samples in a few hours.
BeviMed is thus capable of handling with ease the de-
mands of modern genomic datasets in the coding and
the regulatory regions of the genome.erican Journal of Human Genetics 101, 104–114, July 6, 2017 111
Figure 3. Posterior Probability of Pathogenicity for Rare Vari-
ants in RNU4ATAC
Results of applying the inference procedure to rare allele counts
in RNU4ATAC against the Roifman syndrome case label. The bar
chart on the right shows the marginal posterior probabilities of
pathogenicity for each rare variant conditional on an association
being present at the locus. The inference algorithm was run with
100,000 iterations instead of the usual 1,000 in order to reduce
jitter due to Monte Carlo sampling error. The bar chart on the
left shows the breakdown of heterozygous and homozygous car-
riers of the variants in case and control subjects. Compound het-
erozygous individuals with two rare alleles in RNU4ATAC were
112 The American Journal of Human Genetics 101, 104–114, July 6, 2Appendix A
Inference on presence of an association is based on the
posterior probability of the model indicator g, which can
be derived from the evidence under each model and the
prior on g:
Pðg ¼ 1 j yÞ ¼ Pðy j g ¼ 1ÞPðg ¼ 1ÞP
u˛f0;1g
Pðy j g ¼ uÞPðg ¼ uÞ:
The evidence for the baseline model, Pðy jg ¼ 0Þ, can be
computed efficiently using the beta function:
B

a0 þ
P
iyi; b0 þN 
P
iyi

Bða0; b0Þ
:
The evidence for the association model, Pðy jg ¼ 1Þ, can
be expressed by conditioning on the different modes of
inheritance and summing:
Pðy j g ¼ 1Þ ¼ Pðy j g ¼ 1;m ¼ mdomÞPðm ¼ mdom j g ¼ 1Þ
þ Pðy j g ¼ 1;m ¼ mrecÞPðm ¼ mrec j g ¼ 1Þ;
where Pðy jg ¼ 1;mÞ is given by:X
z˛f0;1gk
ZN
N
ZN
N
pðy j z;mÞpðz j u;fÞpðuÞpðfÞ du df:
For brevity, we have omitted the hyperparameters at, bt,
ap, and bp from the conditioning in pðy j z;mÞ above.
The likelihood pðy j z;mÞ factorizes into two components
corresponding to individuals with and without a patho-
genic combination of alleles, where the rate parameters t
and p can be integrated out analytically. Thus the likeli-
hood can be expressed in closed form:
B

at þ
P
iyi

1 xðzÞi

; bt þ
P
i

1 yi

1 xðzÞi

Bðat; btÞ
3
B

ap þ
P
iyix
ðzÞ
i ; bp þ
P
i

1 yi

x
ðzÞ
i

Bðap; bpÞ
;
(Equation A1)
where x
ðzÞ
i ¼ f ðGi,; z; si;mÞ.As noted in the main text, we use a logit-beta prior on u,
that is:
expitðuÞ  Betaðau; buÞ:
Thus, when cj ¼ 0cj˛f1;.; kg, z is independent of f,
and both u and f can be integrated out:
pðzÞ ¼
B

au þ
P
jzj; bu þ k
P
jzj

Bðau; buÞ
:
By default, au ¼ 2 and bu ¼ 8. The space of z grows
exponentially with the number of variants k, which canobserved, and for each such individual a line is drawn linking
the two variants.
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run into the dozens or hundreds. Therefore, despite the
formulation of themodel enablingmany of the parameters
to be integrated out analytically, the expression for the in-
tegrated likelihood cannot be evaluated in practice. Below
we describe an alternative method to estimate the inte-
grated likelihood which is computationally tractable.
The method of power posteriors10 allows us to estimate
Pðy jg ¼ 1;mÞ by sampling from Pðz j y;mÞtPðzÞ at temper-
atures t ˛ft0 ¼ 0;.; tL ¼ 1g using MCMC. Let ~zðbÞl be the
bth sample drawn at temperature tl. The log integrated like-
lihood log Pðy jg ¼ 1;mÞ can then be estimated by:
XL1
l¼0
log
 
1
j ~zl j
Xj ~zl j
b¼1
eðtlþ1tlÞ log Pðy j~z
ðbÞ
l ; mÞ
!
: (Equation A2)
Running Markov chains at different temperatures
concurrently allows exchanges of state between chains at
adjacent temperatures, which encourages good mixing. If
the Kullback-Leibler (KL) divergence between adjacent po-
wer posterior distributions is large, the resulting estimates
of Pðy jg ¼ 1;mÞ may be susceptible to substantial numer-
ical error. The method that minimizes this error involves
tuning the temperatures using a procedure such as interval
bisection24 and subsequently re-generating the chains to
allow mixing between them. By default we use a pre-
selected set of temperatures t ¼ ðl=6Þ2 for l˛f0;1;.;6g,
and draw 1,000 samples from each chain. This works
well in practice and avoids the need to discard an initial
set of MCMC samples for tuning the temperatures.
The use of MCMC to tackle this overall inference prob-
lem is in contrast to other methods designed for similar
purposes,12,25 probably because of the stringent require-
ments for computational speed. However, our algorithm
contains features that makes MCMC sampling efficient.
In each chain, Gibbs sampling is used to update each in-
dividual component of z in turn. An update to zj consists of
sampling from its full conditional distribution:
Bernoulli
 
1þ p

y j zð0Þ;mpzð0Þ j u;f
pðy j zð1Þ;mÞpðzð1Þ j u;fÞ
1!
;
where z
ð0Þ
j0 ¼ zð1Þj0 ¼ zj0 for j0sj and zð0Þj ¼ 0; zð1Þj ¼ 1.
During the course of the algorithm, we keep track of
xi ¼ f ðGi,; z; si;mÞ for each individual. Given an update of
a single component of z, only individuals for whom Gij >
0 need to have their corresponding value of xi updated. G
is often sparse as it typically represents rare allele counts,
allowing this operation to be performed quickly. If values
for c are specified, then u and f are updated using a
Metropolis Hastings within Gibbs.
Averaging over the space of all variant/variable sets using
MCMC is a daunting challenge, in particular in circum-
stances such as these where non-additive models for the
interaction effects of the variables are used. However, in
practice, there is little collinearity between rare variant allele
counts in unrelated individuals, rare allele count matrices
are sparse, and the interactioneffects indominant andreces-The Amsive inheritance are quite simple, leading to low correlation
between the elements of z. This means that the sampling
procedure can explore the space of z efficiently.
However, when k is large and the mode of inheritance is
recessive, with some case subjects being compound hetero-
zygous, mixing of the MCMC sampler could potentially be
poor if only one element of z is updated at a time. In partic-
ular, it could be very rare for theMarkov chain to transition
from a state satisfying zj1 ¼ zj2 ¼ 0 for some truly patho-
genic variants j1, j2, to a state where zj1 ¼ zj2 ¼ 1, as there
may be no intermediate state that would lead to an in-
crease in likelihood. This is particularly problematic if the
prior on u is concentrated near 0. Thus, under m ¼ mrec,
we propose updates to elements of z corresponding to var-
iants occurring in the same individuals in tandem, which
overcomes the potential rarity of sampling a state with a
high likelihood.
The likelihood shown in Equation A1 can be expressed in
terms of ratios of gamma functions with arguments that
differ by integer amounts less than or equal to the number
of individuals.Hence, thedifferencesbetweenallpossible re-
turnvaluesof log G that are requiredby theprocedure canbe
computed before commencing the sampling and stored to
avoid evaluating the log G function repeatedly. Evaluating
log G is the computational bottleneck in the Markov chain
updates, and replacing itwith look-ups in the pre-computed
values tables results in significant speed-ups.
To further improve computational efficiency while
maintaining adequate precision, the implementation pro-
vides an option to stop sampling once the estimated evi-
dence lies within a given confidence interval, or once there
is sufficient confidence that the log evidence is below a
given threshold. This behavior is implemented based on
the method of consistent batch means.26 The log evidence
is the sum of the logarithms of expectations taken with
respect to the power posteriors (Equation A2), so the cen-
tral limit theorem does not apply and we estimate the con-
fidence interval by simulation.
The samples drawn from the MCMC routine at the tem-
perature t ¼ 1 can be used to compute the expected
number of case subjects whose risk was due to their path-
ogenic configuration of alleles, Ez j y
P
iyix
ðzÞ
i , and the ex-
pected number of variants involved in the explanation,
Ez j y
P
j˛fj0:
P
i
Gij0 yix
ðzÞ
i
>0gzj.
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